Stevanato Group (NYSE:STVN – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.700-0.720 for the period, compared to the consensus EPS estimate of 0.680. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.
Stevanato Group Stock Performance
STVN stock traded up €0.53 on Wednesday, reaching €20.18. The company’s stock had a trading volume of 82,342 shares, compared to its average volume of 542,246. Stevanato Group has a 52 week low of €12.89 and a 52 week high of €28.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.63 and a quick ratio of 1.11. The company has a market capitalization of $6.11 billion, a P/E ratio of 34.20, a price-to-earnings-growth ratio of 1.84 and a beta of 0.77. The firm has a fifty day moving average of €18.70 and a two-hundred day moving average of €16.97.
Stevanato Group (NYSE:STVN – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The business had revenue of €273.57 million for the quarter. During the same period in the previous year, the business earned $0.10 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, analysts predict that Stevanato Group will post 0.71 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Stevanato Group
Insider Activity at Stevanato Group
In other Stevanato Group news, Director Karen Flynn sold 1,493 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of €17.09, for a total value of €25,515.37. Following the transaction, the director directly owned 5,757 shares in the company, valued at €98,387.13. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Madhavan Balachandran sold 1,493 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of €17.09, for a total transaction of €25,515.37. Following the transaction, the director directly owned 69,458 shares of the company’s stock, valued at €1,187,037.22. This represents a 2.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 5,972 shares of company stock worth $102,061.
Stevanato Group News Summary
Here are the key news stories impacting Stevanato Group this week:
- Positive Sentiment: Second-quarter revenue increased 8% year over year to €302.0 million, while high-value solutions accounted for 45% of sales. The company also reported an improvement in gross profit margin, supporting the view that sales growth is translating into better profitability. Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
- Positive Sentiment: Adjusted quarterly earnings were reported at $0.16 per share, above the $0.15 consensus estimate and up from $0.12 a year earlier. The earnings beat likely reinforced investor confidence in the company’s operating performance. Stevanato Group Q2 Earnings Top Estimates
- Positive Sentiment: Stevanato raised its fiscal 2026 EPS guidance to $0.700-$0.720, above the $0.680 analyst consensus. It also targets adjusted EBITDA of approximately €335 million to €345.2 million following the Balda C. Brewer divestiture, signaling continued confidence in earnings and cash-generation prospects. Stevanato Targets 2026 Adjusted EBITDA
- Neutral Sentiment: Full-year revenue guidance of roughly $1.5 billion is broadly in line with consensus, suggesting the main upside surprise is coming from profitability rather than sales expectations.
- Negative Sentiment: One reported earnings measure showed EPS of €0.14, below the €0.15 consensus estimate. The differing adjusted and reported figures could create some uncertainty, although the adjusted earnings beat and higher guidance appear to have dominated the market reaction. Stevanato Group Earnings Report
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in STVN. GW&K Investment Management LLC raised its stake in Stevanato Group by 76.2% in the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after acquiring an additional 1,055 shares during the period. State of Wyoming grew its position in shares of Stevanato Group by 39,216.7% in the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Stevanato Group during the 3rd quarter worth about $68,000. Tower Research Capital LLC TRC grew its holdings in Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after buying an additional 4,250 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Stevanato Group in the fourth quarter worth about $214,000.
About Stevanato Group
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
Featured Articles
- Five stocks we like better than Stevanato Group
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
- Is ADM’s Rally Getting Ahead of Its Policy Tailwind?
- CoreWeave Powers Up: The Asia Infrastructure Grab
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
